Alexander Trockenbacher

Title: Alexander Trockenbacher: Innovator in Disease Treatment

Introduction

Alexander Trockenbacher is a notable inventor based in Innsbruck, Austria. He has made significant contributions to the field of medical science, particularly in the treatment of diseases associated with microtubule-associated protein phosphatase 2A (PP2Ac). His innovative approach has the potential to impact the lives of many individuals affected by these conditions.

Latest Patents

Trockenbacher holds a patent for a method aimed at treating diseases correlated with or caused by non-physiological levels of PP2Ac. The patent describes a method of administering a pharmaceutically effective amount of proteins such as MID1 or MID2, or nucleic acids encoding these proteins, to subjects affected by these diseases. Additionally, it outlines a method for treating conditions associated with decreased intracellular levels of PP2Ac, utilizing peptidic fragments of MID1 or MID2, among other therapeutic strategies.

Career Highlights

Trockenbacher is affiliated with the Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., where he has been able to further his research and development efforts. His work has garnered attention for its innovative approach to addressing complex medical issues.

Collaborations

He has collaborated with esteemed colleagues such as Susann Schweiger and Hans-Hilger Ropers, contributing to a rich environment of scientific inquiry and innovation.

Conclusion

Alexander Trockenbacher's work exemplifies the spirit of innovation in the medical field, particularly through his patent addressing critical health issues related to PP2Ac. His contributions are paving the way for new treatment methodologies that could benefit many patients in the future.